Optimizing Outcomes For Patients With Lung Cancer: Checkpoint Inhibitor Therapy in SCLC and Improving Health Literacy
VINDICO
8/26/20, 11:00 PM
America/New York GMT -4 summer
Description
Lung cancer continues to be the major cause of cancer-related death worldwide. Advances in diagnosis and treatment of lung cancer are helping to improve the management of these patients, yet health disparities persist. Many of these disparities are difficult to overcome, yet strategies to address others such as health literacy are currently being evaluated. Small-cell lung cancer (SCLC), which accounts for approximately 13% of all lung cancer cases, is the most aggressive type of lung cancer and is associated with rapid recurrence and poor prognosis. Immune checkpoint inhibitors alone or in combination with chemotherapy have been demonstrated to be an effective therapeutic option providing overall survival benefits to SCLC patients. In this educational symposium, experts in the field will evaluate checkpoint inhibitors in the management of SCLC, discuss health disparities in lung cancer, and provide guidance to address health literacy in patients with lung cancer.
Previous registration necessary?
NO
YES
Simultaneous translation ?
NO
YES
Will it be recorded?
NO
YES
Optimizing Outcomes For Patients With Lung Cancer: Checkpoint Inhibitor Therapy in SCLC and Improving Health Literacy
Inglês
Speakers
George R. Simon, Yasir Y. Elamin, Sarah Anderson, Kelly Brassil
Link to the Event
Banner to the Event
Register your event here
Already have an account? LOGIN HERE. If You don't have an account you need to create a free account.